anovulatory WHO class II women, ovulatory with clomiphene citrate.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. WHO class II anovulatory women who ovulate following use of incremental CC doses from 50 to 150 mg starting on dag 3-5 following 5 days of the cycle; 2. All patients have normal serum prolactin (0,05 ¨C 0,80 IU/l) and thyroid-stimulating hormone (0,4 - 4,0 mU/l); 3. Age > 18 years; 4. A partner with total motile sperm count above 1 million, according to the modified criteria of the World Health Organization (1999).
Exclusion criteria
Exclusion criteria: 1. Women who remain anovulatory on CC 150 mg or who become anovulatory after initial ovulation; 2. Known bilateral tubal obstruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the occurrence of an ongoing, vital intra-uterine singleton pregnancy. An ongoing, vital pregnancy is defined as fetal heart beat seen by transvaginal ultrasonography at 12 weeks gestation. If no pregnancy occurs, follow-up ends after the sixth cycle. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Positive pregnancy test; 2. Occurrence of ovulation; 3. Total number of postcoital tests performed; 4. Median time to pregnancy; 5. Clinical pregnancy, defined as any registered heart beat at sonography; 6. Miscarriage, defined as loss of an intra uterine pregnancy (confirmed by ultrasound or histologic examination) before the 20th week of pregnancy; 7. Multiple pregnancy, defined as a registered heart beat of at least two fetuses at 12 weeks of gestation. | — |
Contacts
Medisch Spectrum Twente Locatie Enschede Ariënsplein